EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials (2021)

Government Record · European Medicines Agency · March 22, 2021

European Medicines Agency, 2021-03-22: The EU regulator's March 2021 statement that the data do not support ivermectin for COVID-19 outside well-designed trials, noting that laboratory activity occurs only at concentrations above those achieved with authorised doses.

EMA has reviewed the latest evidence on the use of ivermectin for the prevention and treatment of COVID-19 and concluded that the available data do not support its use for COVID-19 outside well-designed clinical trials.

European Medicines Agency, 2021-03-22: The EU regulator's March 2021 statement that the data do not support ivermectin for COVID-19 outside well-designed trials, noting that laboratory activity occurs only at concentrations above those achieved with authorised doses. Regulatory news statement (EU). It records that ivermectin tablets are approved in the EU for some parasitic worm infestations and skin preparations for conditions such as rosacea, that ivermectin is not authorised for COVID-19 in the EU and no application has been received, and that most reviewed studies were small with differing dosing regimens. No study population. Date 2021-03-22 is the publication date carried on the EMA item. Study type: regulatory record.